Loading briefing details...
News Abstract
By: PointLine Media Research & Editorial Team
Topic:Business,Government,Health,Industry,Lifestyle
July 27, 2026
ADAP Advocacy is calling for a major shift in how the federal 340B Drug Pricing Program is managed. The group wants oversight moved from the Health Resources and Services Administration (HRSA) to the Centers for Medicare and Medicaid Services (CMS) to improve regulatory enforcement.
The organization argues that the current program has strayed from its original purpose. While designed to help underserved patients access affordable medicine, advocates claim that provider interests are now consistently prioritized over patient needs.
Research from the group indicates a lack of transparency regarding how hospitals use 340B-generated revenue. Findings showed that a significant number of hospitals actually reduced their charity care spending after gaining access to the program's benefits.
The 340B program has evolved into the second-largest federal prescription drug initiative in the U.S., reaching over $100 billion in annual sales. However, the program's rapid growth has sparked intense debate over accountability and the actual impact on patient access to care.
As healthcare costs continue to climb, regulators are facing increased pressure to ensure that institutions benefiting from federal drug discounts are reinvesting those savings into community health initiatives. This push for oversight reflects a broader trend of demanding greater transparency in hospital financial practices.